CIK 0001001233
- Non-accelerated filer
- Smaller reporting company
SANGAMO THERAPEUTICS, INC
Sign in to watch- Ticker
- SGMOQ
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680359556
- Phone
- +1 510-970-6000
- Business address
- 501 CANAL BLVD., RICHMOND, CA, 94084
- Former names
- SANGAMO BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-25 | Dubois-Stringfellow Nathalie SVP-Chief Development Officer | Shares withheld for taxes | −1,462 | $1.33 | $2K | 137,096 |
| 2023-05-25 | Fontenot Jason D. SVP, Chief Scientific Officer | Shares withheld for taxes | −1,029 | $1.33 | $1K | 138,329 |
| 2023-05-25 | Duraibabu Prathyusha SVP, Chief Financial Officer | Shares withheld for taxes | −1,328 | $1.33 | $2K | 132,052 |
| 2023-05-25 | Macrae Sandy President, CEO and Director | Shares withheld for taxes | −10,411 | $1.33 | $14K | 613,298 |
| 2023-04-24 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Shares withheld for taxes | −3,977 | $1.65 | $7K | 126,612 |
| 2023-03-25 | Duraibabu Prathyusha SVP, Chief Financial Officer | Shares withheld for taxes | −345 | $1.66 | $573 | 133,380 |
| 2023-02-25 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Shares withheld for taxes | −5,128 | $2.66 | $14K | 130,589 |
| 2023-02-25 | Ramelmeier Rolf Andrew EVP, Technical Operations | Shares withheld for taxes | −15,618 | $2.66 | $42K | 173,217 |
| 2023-02-25 | McClung David Mark EVP, Chief Operating Officer | Shares withheld for taxes | −9,745 | $2.66 | $26K | 224,774 |
| 2023-02-25 | Dubois-Stringfellow Nathalie SVP-Chief Development Officer | Shares withheld for taxes | −9,834 | $2.66 | $26K | 138,558 |
| 2023-02-25 | Fontenot Jason D. SVP, Chief Scientific Officer | Shares withheld for taxes | −6,559 | $2.66 | $17K | 139,358 |
| 2023-02-25 | Duraibabu Prathyusha SVP, Chief Financial Officer | Shares withheld for taxes | −7,030 | $2.66 | $19K | 133,725 |
| 2023-02-25 | Macrae Sandy President, CEO and Director | Shares withheld for taxes | −54,767 | $2.66 | $146K | 623,709 |
| 2023-02-24 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Grant or award | +42,750 | 135,717 | ||
| 2023-02-24 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Grant or award · Stock Option (Right to Buy) | +199,500 | 199,500 | ||
| 2023-02-24 | Ramelmeier Rolf Andrew EVP, Technical Operations | Grant or award | +45,000 | 188,835 | ||
| 2023-02-24 | Ramelmeier Rolf Andrew EVP, Technical Operations | Grant or award · Stock Option (Right to Buy) | +210,000 | 210,000 | ||
| 2023-02-24 | McClung David Mark EVP, Chief Operating Officer | Grant or award | +56,250 | 234,519 | ||
| 2023-02-24 | McClung David Mark EVP, Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +262,500 | 262,500 | ||
| 2023-02-24 | Dubois-Stringfellow Nathalie SVP-Chief Development Officer | Grant or award | +53,438 | 148,392 |
Page 11 of 17 · 338 trades